Sigmoid Pharma Limited – Product Pipeline Review

Global Markets Direct’s, ‘Sigmoid Pharma Limited – Product Pipeline Review – 2016’, provides an overview of the Sigmoid Pharma Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sigmoid Pharma Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Sigmoid Pharma Limited

The report provides overview of Sigmoid Pharma Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Sigmoid Pharma Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Sigmoid Pharma Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Sigmoid Pharma Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sigmoid Pharma Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sigmoid Pharma Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Sigmoid Pharma Limited Snapshot 5

Sigmoid Pharma Limited Overview 5

Key Information 5

Key Facts 5

Sigmoid Pharma Limited - Research and Development Overview 6

Key Therapeutic Areas 6

Sigmoid Pharma Limited - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Combination Treatment Modalities 10

Sigmoid Pharma Limited - Pipeline Products Glance 11

Sigmoid Pharma Limited - Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Sigmoid Pharma Limited - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

Sigmoid Pharma Limited - Drug Profiles 15

cyclosporine CR 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

cyclosporine 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

cyclosporine CR + cyclosporine IR 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

cyclosporine IR 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

calcitonin 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

dimethyloxalylglycine 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Helicobacter pylori [strain Hel-305] (multivalent) vaccine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

celecoxib 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Drugs for Gastrointestinal and Immunological Disorders 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Drugs to Agonize FXR for Undisclosed Indication 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecules for Undisclosed Indication 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Sigmoid Pharma Limited - Pipeline Analysis 26

Sigmoid Pharma Limited - Pipeline Products by Target 26

Sigmoid Pharma Limited - Pipeline Products by Route of Administration 27

Sigmoid Pharma Limited - Pipeline Products by Molecule Type 28

Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action 29

Sigmoid Pharma Limited - Recent Pipeline Updates 30

Sigmoid Pharma Limited - Locations And Subsidiaries 31

Head Office 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Tables

List of Tables

Sigmoid Pharma Limited, Key Information 5

Sigmoid Pharma Limited, Key Facts 5

Sigmoid Pharma Limited – Pipeline by Indication, 2016 7

Sigmoid Pharma Limited – Pipeline by Stage of Development, 2016 8

Sigmoid Pharma Limited – Monotherapy Products in Pipeline, 2016 9

Sigmoid Pharma Limited – Combination Treatment Modalities in Pipeline, 2016 10

Sigmoid Pharma Limited – Phase II, 2016 11

Sigmoid Pharma Limited – Phase I, 2016 12

Sigmoid Pharma Limited – Preclinical, 2016 13

Sigmoid Pharma Limited – Discovery, 2016 14

Sigmoid Pharma Limited – Pipeline by Target, 2016 26

Sigmoid Pharma Limited – Pipeline by Route of Administration, 2016 27

Sigmoid Pharma Limited – Pipeline by Molecule Type, 2016 28

Sigmoid Pharma Limited – Pipeline Products by Mechanism of Action, 2016 29

Sigmoid Pharma Limited – Recent Pipeline Updates, 2016 30

List of Figures

List of Figures

Sigmoid Pharma Limited – Pipeline by Top 10 Indication, 2016 7

Sigmoid Pharma Limited – Pipeline by Stage of Development, 2016 8

Sigmoid Pharma Limited – Monotherapy Products in Pipeline, 2016 9

Sigmoid Pharma Limited – Pipeline by Target, 2016 26

Sigmoid Pharma Limited – Pipeline by Route of Administration, 2016 27

Sigmoid Pharma Limited – Pipeline by Molecule Type, 2016 28

Sigmoid Pharma Limited – Pipeline Products by Mechanism of Action, 2016 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports